BioSpace News Archive

Third-Quarter 2019 Net Sales of $335.5 Million Increased 3 Percent; Third-Quarter 2019 GAAP Net Income of $18.2 Million; Adjusted EBITDA of $130.4 Million

LabCorp®, a leading global life sciences company, announced that John Ratliff is departing the company to pursue another opportunity.

Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, provided a business update and reported financial results for the third quarter ended September 30, 2019.

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, announced that the Company will host a conference call and live webcast on Wednesday, November 13, 2019 at 8:00 a.m.

Oncology Pharma Inc. is pleased to announce that it has entered into an agreement with Ribera for its clinical trial platform, “Connect2Med”.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical development activities and reported its financial results for the third quarter ended September 30, 2019.

Net revenue of $7.2 million in the third quarter of 2019, representing 78% growth compared to the third quarter of 2018

The Inducement Awards were made outside of the company’s current equity plan, but are subject to terms and conditions generally consistent with those in the company’s 2016 Equity Incentive Plan.

Discovery marks the first time a new subtype of HIV-1 has been identified since 2000

Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), today announced that it will host a conference call at 1:00 PM Eastern Time on Wednesday, November 13, 2019 to discuss the Company’s financial results for the second quarter ended September 30, 2019,